30 September 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Participation in The Small Cap Showcase

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that members of its executive management team will participate in The Small Cap Showcase on Thursday 1 October 2026 in New York City.

Dr Sotirios Stergiopoulos, Chairman and Stephen West, Non-Executive Director will present at 11:00 a.m. ET (4 p.m. BST), providing an overview of its business strategy, growth opportunities, recent developments and outlook. Management will also participate in one-on-one meetings with pre-qualified investors throughout the day.

A live webcast of the Company's presentation will be available at: https://www.webcaster5.com/Webcast/Page/3173/54585

The Small Cap Showcase is an investor-focused conference connecting executive management teams from approximately 12 micro- and small-cap public companies with institutional and other qualified investors. The event is designed to provide investors with meaningful access to differentiated small-cap investment opportunities through company presentations, one-on-one meetings and networking throughout the day.

For more information about The Small Cap Showcase, please visit www.smallcapshowcase.com.

-Ends-

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.

By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.

The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.